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Abstract
Background: Diadenosine tetraphosphate (Ap4A), a constituent of platelet dense granules, and its P
1,P4-dithio and/or P2,P3-
chloromethylene analogs, inhibit adenosine diphosphate (ADP)-induced platelet aggregation. We recently reported that
these compounds antagonize both platelet ADP receptors, P2Y1 and P2Y12. The most active of those analogs, diadenosine
59,500-P1,P4-dithio-P2,P3-chloromethylenetetraphosphate, (compound 1), exists as a mixture of 4 stereoisomers.
Objective: To separate the stereoisomers of compound 1 and determine their effects on platelet aggregation, platelet P2Y1
and P2Y12 receptor antagonism, and their metabolism in human plasma.
Methods: We separated the 4 diastereomers of compound 1 by preparative reversed-phase chromatography, and studied
their effect on ADP-induced platelet aggregation, P2Y1-mediated changes in cytosolic Ca
2+, P2Y12-mediated changes in
VASP phosphorylation, and metabolism in human plasma.
Results: The inhibition of ADP-induced human platelet aggregation and human platelet P2Y12 receptor, and stability in
human plasma strongly depended on the stereo-configuration of the chiral P1- and P4-phosphorothioate groups, the SPSP
diastereomer being the most potent inhibitor and completely resistant to degradation in plasma, and the RPRP diastereomer
being the least potent inhibitor and with the lowest plasma stability. The inhibitory activity of SPRP diastereomers depended
on the configuration of the pseudo-asymmetric carbon of the P2,P3-chloromethylene group, one of the configurations
being significantly more active than the other. Their plasma stability did not differ significantly, being intermediate to that
of the SPSP and the RPRP diastereomers.
Conclusions: The presently-described stereoisomers have utility for structural, mechanistic, and drug development studies
of dual antagonists of platelet P2Y1 and P2Y12 receptors.
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Introduction
Platelets express two G-protein-coupled P2Y (nucleotide acti-
vated) receptors, P2Y1 and P2Y12 [1]. Both receptors are activated
by adenosine 59-diphosphate (ADP) and play essential and
mutually dependent roles in the process of platelet activation
and aggregation [1]. Gq coupled P2Y1 activates the beta-isoform
of phospholipase C (PLCb) and causes inositol 1,4,5-trisphosphate
(IP3)-mediated increase in intracellular calcium levels, mainly by
calcium release from intracellular stores. P2Y1 activation initiates
ADP-induced platelet aggregation and results in platelet shape
change [1]. However, without P2Y12 activation, the result is a
small and reversible platelet aggregation. Gi-coupled P2Y12
inhibits adenylyl cyclase, thereby stimulating phosphatidylinosi-
tol-3 kinase (PI-3K) activity. Reduced cAMP levels further reduce
cAMP dependent protein kinase A phosphorylation of vasodilator-
stimulated phosphoprotein (VASP), a modulator of platelet
cytoskeletal proteins [2]. Functionally this results in potentiation
of platelet secretion, and amplification and stabilization of the
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aggregation response. There is a complex interplay between P2Y1
and P2Y12, and co-activation of both receptors, or the signaling
pathways they trigger is necessary for full platelet aggregation to
take place [3].
Diadenosine 59,590-tetraphosphate (Ap4A, Figure 1) is the most
important member of the group of dinucleoside polyphosphates. It
is found in a variety of cells, is secreted extracellularly, and is
involved in the regulation of variety of intra- and extracellular
physiological functions [4]. In platelets Ap4A is stored in dense
granules and is therefore released along with ADP and ATP upon
platelet activation [5]. Early studies of diadenosine polyphosphates
found that diadenosine triphosphate induces platelet aggregation
and that Ap4A antagonizes this effect [6]. It is now well known that
Ap4A inhibits ADP-induced platelet activation [7], and a number
of Ap4A analogs with modifications in the tetraphosphate chain
have been synthesized and studied with the aim to improve on this
effect and to increase the biological stability [8–10]. We recently
reported that Ap4A and its P
1- and/or P4-thio, and P2,P3-
chloromethylene analogs inhibit platelet aggregation by targeting
both P2Y1 and P2Y12 receptors [11,12]. The most potent of these
analogs for inhibition of platelet aggregation, diadenosine 59,500-
P1,P4-dithio-P2,P3-chloromethylenetetraphosphate, (compound 1,
Figure 1) [8,12] has thio substitutions at the two terminal
phosphate groups, which render the corresponding phosphorus
atoms (P1 and P4) chiral. This, together with the pseudo-
asymmetric carbon atom of chloromethylene group between P2
and P3 [13] gives rise to 4 stereoisomers for compound 1 [14] (See
Discussion for details).
Phosphorothioate stereoisomers, in general, differ significantly
in their substrate or ligand properties [15,16], a fact which has
been used extensively for various mechanistic studies [17].
Considering that platelet P2 receptors may exhibit stereoselectivity
for the stereoisomers of 1 we preparatively separated its four
diastereomers and studied their actions on ADP-induced human
platelet aggregation, human platelet P2Y1 and P2Y12 receptors
antagonism, and their stability and metabolism in human plasma.
We found that the stereo configuration at P1 and P4 has significant
effects on platelet aggregation, P2Y12 antagonism and plasma
stability, and lesser effect on P2Y1 antagonism. Compounds with
SP configuration at both P
1 and P4 have the highest platelet
aggregation and P2Y12 inhibitory potency and highest stability in
plasma.
Materials and Methods
Materials
Compound 1 was prepared as previously described [18].
Adenosine 59-(P1-thio-P2,P3-chloromethylenetriphosphate), com-
pound 2 was isolated as a minor byproduct during the synthesis of
1 and was characterized by 1H, and 31P NMR and liquid
chromatography-mass spectrometry (LCMS). Adenosine 59-thio-
monophosphate (thioAMP), MRS2179, probenecid, adenosine 59-
(b,c-methylenetriphosphate) (b,c-CH2-ATP), ethylene glycol tetra-
acetic acid (EGTA) and apyrase (grade VII) were purchased from
Sigma-Aldrich (St. Louis, MO). D-Phenylalanyl-L-prolyl-L-argi-
nine chloromethyl ketone (PPACK) was purchased from Calbio-
chem (La Jolla, CA). FLUO-4 was from Invitrogen (Carlsbad,
CA), ADP from Bio/Data (Horsham, PA), CD41-phycoerythrin
(PE)-Cy5 from Beckman Coulter (Fullerton, CA). The VASP
phosphorylation kit was purchased from BioCytex (Marseilles,
France).
Separation of the diastereomers of compound 1
Analytical separation of the diastereomers of compound 1 by
reversed-phase high performance liquid chromatography (HPLC)
has been described [14]. In the present work we used a
modification of this method, utilizing a XBridge RP C18
3.5 mm, 4.66150 mm column with a 4.6610 mm guard column
(Waters Inc., Waltham, Mass. USA), and a binary linear gradient
from 100% of mobile phase A to 35% of mobile phase B in A for
35 min (A was 20 mM potassium phosphate buffer with pH 7,
and B was 20% methanol in A) at 1 ml/min, 30uC column
temperature, and UV detection at 260 nm.
Preparative separation was done on an XBridge C18 5 mm,
206250 mm preparative column at 20 ml/min, all other condi-
Figure 1. Chemical structure and stereo-configuration of the
stereoisomers of diadenosine 59,500-P1,P4-dithio-P2,P3-chloro-
methylenetetraphosphate (compound 1), and of adenosine 59-
(P1-thio-P2,P3-chloromethylenetriphosphate), (compound 2).
RP and SP designate the absolute configuration of chiral P
1- and P4-
phosphorothioates; r and s, the absolute configuration of the pseudo-
asymmetric carbon of the P2,P3-chloromethylene group in compound
1; R and S, the absolute configuration of the chloromethylene group in
compound 2. Ade, 59-adenosyl; N.A., Not Asymmetric.
doi:10.1371/journal.pone.0094780.g001
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tions being the same as at the analytical runs. The fractions
containing the separated diastereomers were pooled and concen-
trated under vacuum, and then desalted on the same column using
volatile triethylammonium bicarbonate (TEAB) buffer, and a
15 min gradient from 0.2 M TEAB to 50% methanol in 0.2 M
TEAB at 20 ml/min. The desalted fractions were evaporated
under vacuum and the residual TEAB buffer was removed by
repeated evaporation from methanol. Finally each diastereomer
was converted to the sodium salts by passing through a column of
Dowex W50X2 (5620 mm) in the sodium form, followed by
lyophilization. The isolated diastereomers were characterized by
proton and phosphorous NMR and by mass spectrometry. Stock
solutions (10 mM) in water were prepared using molar absorptivity
of 20.2 mM21cm21 at 260 nm [8], and were stored frozen at
280uC.
Ethics Statement
This study was approved by the University of Massachusetts
Medical School Institutional Review Board (IRB). Written IRB-
approved informed consent was obtained prior to blood collection.
Blood collection and sample preparation
Human blood samples were taken from healthy volunteer
donors free from aspirin or other non-steroidal anti-inflammatory
drugs for more than 7 days. Blood was drawn from antecubital
veins into tubes containing 3.2% sodium citrate. For platelet
aggregation assays the blood was centrifuged at 1106 g for 12
minutes, and platelet-rich plasma (PRP) was immediately
removed. Centrifugation at 16506g for 10 minutes was to obtain
platelet-poor plasma (PPP).
ADP-induced platelet aggregation
The 96-well microplate method for the detection of ADP-
induced platelet aggregation and the concentration dependence of
its inhibition by the tested compounds was used as previously
described [11,12], thereby avoiding the problem of platelet aging
[19,20]. In brief, PRP at 37uC was added to a pre-warmed 96-well
microplate containing ADP (3 mM final concentration) and test
compounds (various concentrations) or vehicle (10 mM Hepes,
0.15 M NaCl, pH 7.4). Light transmission at 580 nm was
recorded immediately and at 11 second intervals for 6 min at
37uC with intermittent programmed shaking of the plate in a
Molecular Devices microplate reader. Within each experiment all
samples were run in duplicate and each experiment was repeated
3–5 times with PRP from different donors.
P2Y12-mediated vasodilator-stimulated phosphoprotein
(VASP) phosphorylation assay
VASP phosphorylation was measured by flow cytometry using a
BioCytex kit, essentially according to the manufacturer’s recom-
mendations, except that a small volume of the test compound
solution or vehicle (HEPES-saline) was added to each assay tube as
previously described [11,12]. Analysis was performed in a
FACSCalibur (Becton Dickinson) flow cytometer.
P2Y1-mediated cytosolic Ca
2+ increase assay
ADP-dependent, P2Y1-mediated increase in platelet cytosolic
Ca2+ was measured by detecting changes in FLUO-4 fluorescence
as previously described [11,12]. In brief, citrated whole blood was
added to a loading solution consisting of 5 mM FLUO-4, CD41-
PE-Cy5 and 1 mM probenecid, and the mixture was incubated for
30 minutes at room temperature. Samples were diluted 36-fold in
10 mM HEPES, 0.15 M NaCl, pH 7.4 and analyzed in a
FACSCalibur flow cytometer. After obtaining a 30 second
baseline recording, the acquisition was paused, and 60 mL of
ADP (3 mM final concentration) and test compound solutions at
various concentrations or ADP plus vehicle (HEPES-saline) were
quickly added, the sample mixed, and the acquisition resumed
(total pause time less than 10 seconds). FLUO-4 fluorescence
before and after addition of ADP (3 mM final concentration) and
test compound solutions was monitored. The mean FLUO-4
fluorescence of the baseline 30-second interval and of 10-second
post-stimulant intervals was calculated. The cytosolic Ca2+
increase was calculated as the ratio of the maximal post-stimulant
FLUO-4 fluorescence to the baseline FLUO-4 fluorescence. The
percent inhibition of ADP-induced Ca2+ increase due to the
addition of the test compounds was calculated relative to 3 mM
ADP plus vehicle (HEPES-saline).
Stability and metabolism in plasma
Frozen, pooled, heparin-anticoagulated human plasma (BioR-
eclamation, Westbury, NY, catalog # HMPLNAHP) was thawed
upon arrival, aliquoted (2.5 ml) in sterile polypropylene vials, re-
frozen in dry ice, and stored at 220uC. At the time of testing the
plasma aliquots were thawed and incubated at 37uC for 10
minutes. Test compound, 25 mL of 10 mM solution in water
(100 mM final concentration) was added, the sample was mixed
briefly, and incubated at 37uC. Aliquots (100 mL) were taken at the
indicated times, mixed with 35% HClO4 (8 mL), and centrifuged
(10 min, 130006 g). Forty mL supernatant were removed, mixed
with 160 mL of 50 mM K2CO3, and centrifuged (15 min, 130006
g). Supernatant, 150 mL was removed for HPLC analysis. The
chemical stability of the test compounds under the incubation and
work up conditions was controlled by incubation with heat-
inactivated (10 minutes at 95uC) plasma. Plasma incubation
without test compound addition was used for method specificity
control. The external standard calibration was done using plasma
samples, spiked with test compounds, and processed without
incubation. The extraction efficiency was evaluated by analysis of
the calibration samples relative to the analysis of standard samples
in mobile phase, and was above 90%. The main metabolites, the
diastereomers of compound 2 (Figure 1) and thioAMP, were
identified by LCMS analysis of incubation mixtures, and
confirmed by analysis of heat-inactivated plasma samples spiked
with thioAMP and synthetic compound 2.
Statistical analysis
The results were analyzed using GraphPAD Prism software,
version 4.00 for Windows (GraphPad Software, San Diego, CA).
All data are expressed as mean followed by 95% confidence
interval (95% CI). Student’s t-test was used to determine statistical
significance when two groups of data were compared. One-way
ANOVA and Bonferroni’s multiple comparison tests were used
when three or more groups of data were compared. The rate
constants for degradation in plasma and the associated half-lives
were estimated by a non-linear fitting of first order elimination
model to the chromatographic peak areas.
Results
Separation of diastereomers
Excellent separation of the diastereomers of compound 1 was
achieved with 20 mM potassium phosphate buffer at very low (1–
7%) methanol content on a C18 column (Figure 2A). The optimal
pH of the buffer was from 7 to 8. The peak shape quickly
deteriorated at pH values below 6. This method scaled up well on
preparative XBridge C18 5 mm column (256250 mm). After
Ap4A Analog Stereoisomers and Platelet Function
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desalting and conversion to their sodium salts, 1.7, 3.3, 3.8, and
2.4 mg of diastereomers 1.1, 1.2, 1.3, and 1.4, respectively, were
prepared. The purity of each diastereomer was above 95% by
analytical HPLC (Figure 2B). By mass spectroscopy, the isolated
diastereomers were all identical and indistinguishable from the
racemic mixture (data not shown). Characterization by phospho-
rous NMR showed distinct resonance profiles in the P1,P4 and
P2,P3 regions for each of the isolated diastereomers (Figure 3)
consistent with their high purity. The most significant differences
in the proton NMR spectra were in the resonances of the proton of
the monochloromethylene group (see structure in Figure 1), which,
due to the two bond coupling to P2 and P3, were observed as
characteristic triplets (2JP-H = 17.3–17.7 Hz) at 4.675 (1.1), 4.454
(1.2), 4.825 (1.3), and 4.525 (1.4) ppm.
The absolute configurations of the phosphorothioate groups of
the four diastereomers of compound 1 (Figs. 1 and 2) have already
been assigned [14] by using snake venom phosphodiesterase
digestion (See Discussion section for details).
Inhibition of ADP-induced platelet aggregation
Figure 4A shows the dose response curves, determined in
parallel, of the four diastereomers of compound 1 for inhibition of
3 mM ADP-induced platelet aggregation. The IC50s (listed in
Table 1) for diastereomers 1.1 and 1.3 were not significantly
different from each other. The IC50s for diastereomers 1.2 and
1.4 also did not differ significantly from each other, but were both
significantly higher (p,0.0001, F-test) than those for 1.1 and 1.3.
Therefore, the antiaggregatory potency order was
1.1<1.3.1.2<1.4.
Antagonism of platelet P2Y12-mediated, ADP-induced
decrease in VASP phosphorylation
The relative potency of the four diastereomers to inhibit platelet
P2Y12 receptors was tested by their ability, at a single concentra-
tion of 10 mM, to inhibit the ADP-induced decrease of VASP
phosphorylation, an index of platelet P2Y12 receptor activation
[11,12]. The percent inhibitions are shown in Figure 4B and
Table 1. Diastereomer 1.1 was significantly more potent than 1.2
(p,0.05) and 1.4 (p,0.01, Bonferroni’s multiple comparison test),
and did not differ significantly from 1.3. The IC50s for
diastereomers 1.2 and 1.4 also did not differ significantly from
each other. The order of potency was 1.1<1.3.1.2<1.4.
Antagonism of platelet P2Y1-mediated, ADP-induced
increase in cytosolic Ca2+
The relative potency of the individual diastereomers of
compound 1 to inhibit platelet P2Y1 receptors was evaluated at
the single concentration of 10 mM by their ability to reduce 3 mM
ADP-induced intracellular Ca2+ increase due to P2Y1-mediated
Ca2+ release from intraplatelet stores. The percent inhibitions are
shown in Figure 4C and Table 1. Compared with diastereomer
1.1, diastereomer 1.4 was significantly less potent for inhibition of
Figure 2. Reversed-phase HPLC separation of the diastereo-
mers of compound 1. Panel A: chromatogram of the racemic mix of
the diastereomers of compound 1 analyzed by reversed-phase HPLC
using a XBridge C18 column, 3.5 mm, 4.66150 mm (Waters Inc.,
Waltham, Mass. USA), linear gradient from 1 to 7% methanol in
20 mM potassium phosphate buffer, pH 7, 1 ml/min, detection by UV
at 260 nm; Panel B: chromatograms of isolated individual diastereomers
(1.1–1.4) of compound 1 analyzed using the same column and flow
rate, but with isocratic elution with 7% methanol in 20 mM potassium
phosphate buffer, pH 7.
doi:10.1371/journal.pone.0094780.g002
Figure 3. 31P NMR Spectra (1H decoupled) of the diastereomers
of compound 1 and their racemic mixture. In the left panel are the
P1,P4 regions, and in the right panel are the P2,P3 regions of the spectra.
The traces are, from bottom to top: racemic mixture (RM), diastereomer
1.1, 1.2, 1.3, and 1.4.
doi:10.1371/journal.pone.0094780.g003
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platelet P2Y1 function (p,0.05, n= 6, Bonferroni’s multiple
comparison test) while 1.2 and 1.3 did not differ significantly
from 1.1. The order of potency was 1.2.1.1.1.3.1.4.
Metabolism in human plasma
Although compound 1 is very stable in human plasma, by using
very long incubation times we were able to observe clear
Figure 4. Effects of compound 1 diastereomers on platelet aggregation and platelet ADP receptor signaling. Inhibition by the
diastereomers of compound 1 of: A, 3 mM ADP-stimulated platelet aggregation; B, P2Y12 mediated ADP-induced decrease of VASP phosphorylation;
and C, P2Y1-mediated ADP-induced intraplatelet Ca
2+ level increase. VASP, vasodilator-stimulated phosphoprotein. For other abbreviation, see
Figure 1.
doi:10.1371/journal.pone.0094780.g004
Table 1. Platelet-related properties of the four diastereomers of compound 1.
Diastereomer number and
configuration
Platelet Aggregation
(IC50, mM, 95% CI)
P2Y12 VASP
a Phosphorylation
(% inhibition at 10 mM, 95% CI, n =3)
P2Y1 Calcium Flux (% inhibition at
10 mM, 95% CI, n =6)
1.1, SPSP 0.15 (0.09 to 0.24) 97.4 (42.2 to 152.7) 73.2 (58.5 to 87.8)
1.2, SPsRP;SPrRP 0.50 (0.32 to 0.79)b,e 24.3 (217.2 to 65.9)c 85.7 (75.1 to 96.3)
1.3, SPrRP;SPsRP 0.24 (0.14 to 0.40) 81.2 (28.4 to 170.8) 59 (48.5 to 69.5)
1.4, RPRP 0.82 (0.45 to 1.50)
e 12.8 (217.3 to 42.9)d 38.9 (24.1 to 53.6)e
aVASP, vasodilator-stimulated phosphoprotein.
bAll comparisons vs. diastereomer 1.1.
cp,0.05.
dp,0.01.
ep,0.001.
doi:10.1371/journal.pone.0094780.t001
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differences in the rate of degradation and the type of degradation
products of its diastereomers (Figure 5). Diastereomer 1.4
degraded to thioAMP with a half-life (t1/2) of 8.1 hours.
Diastereomers 1.2 and 1.3 degraded with almost equal rates (t1/
2 17.9 and 18.5 hours, respectively) giving equal amounts of
thioAMP and two different stereoisomers of the triphosphate 2,
which were resistant to further hydrolysis. Diastereomer 1.1 was
completely stable in human plasma, with no loss after 96 hours
incubation at 37uC. In fact we did not observe measurable
degradation of this diastereomer even after incubation for 6 days
at 37uC (data not shown). Also, control incubation of the
diastereomeric mixture of 1 at 37uC with heat denatured human
plasma for 6 days showed no decomposition, demonstrating the
remarkable chemical stability of compound 1. The overall order of
stability of the four diastereomers of compound 1 in human
plasma was 1.1.1.2<1.3.1.4.
Discussion
Stereoisomers of compound 1 and their absolute
configuration assignment
The absolute configuration of a phosphorous atoms containing
4 different substituents is designated, according to Ingold-Kahn-
Prelog notation, as RP or SP [21]. The subscript ‘‘P’’ indicates that
this absolute configuration applies to an asymmetric phosphorous,
and not to a carbon atom. The stereochemical character of the
chloromethylene group in compound 1 depends on the absolute
configuration at P1 and P4. When P1 and P4 have the same
configuration (RPRP, SPSP) the carbon atom of the chloromethy-
lene group has two identical substituents, and is not asymmetric.
However, when P1 and P4 are of different configurations
(RPSP;SPRP), this carbon atom becomes pseudo-asymmetric
[13], and can exist in two absolute configurations designated with
r and s. The prefix ‘‘pseudo’’ indicates that this carbon contains
two substituents that differ only in their stereo-configuration, and
lower case r and s, instead of upper case R and S are used for the
same reason. Therefore compound 1 can have 4 different
stereoisomers with configurations SPSP, SPsRP;RPsSP,
SPrRP;RPrSP, and RPRP (SPsRP is identical to RPsSP, and SPrRP
is identical to RPrSP because of the symmetry of the molecule
relative the chloromethylene group, Figure 1). All those stereoiso-
mers are diastereomeric to each other because of the chiral
character of the ribose moiety. Blackburn et al. [14,22] used
digestion with snake venom phosphodiesterase (SVP), and the well
established resistance of phosphorothioates in SP configuration to
hydrolysis by this enzyme [23,24] to assign the absolute
configurations of the four diastereomers of compound 1 and its
closely related monofluoromethylene analog in the order of their
elution (Figure 2) as: 1.1, SPSP; 1.2, SPsRP or SPrRP; 1.3, SPrRP
or SPsRP, and 1.4, RPRP. These assignments are also in
agreement with the well known observation that SP phosphor-
othioates elute earlier the RP isomers [23,24]. The SVP digestion
method does not allow for the determination of the absolute
configuration of the pseudo-asymmetric carbon atom between P2
and P3.
Inhibition of ADP-induced platelet aggregation and
platelet P2Y1 and P2Y12 receptors
Well-defined differences in inhibition of ADP-induced platelet
aggregation and platelet P2Y1 and P2Y12 antagonist properties of
the four diastereomers of compound 1 were observed (Figure 4
and Table 1). The diastereomers of compound 1 could be
separated into two groups based on their potency for inhibition of
platelet aggregation: 1.1, 1.3 and 1.2, 1.4. The differences
between the IC50s within each pair are not statistically significant,
but between the pairs the differences are statistically significant,
1.1 and 1.3 being significantly more active than 1.2 and 1.4. This
same order of potency was observed for the antagonist activity of
the diastereomers toward P2Y12 (Figure 4B), where 1.1 and 1.3
are significantly more active than 1.2 and 1.4. In contrast, 1.2
inhibited P2Y1 with potency similar to that of 1.1 and 1.3 and
greater than that of 1.4 (Figure 4C), yet it had reduced potency for
inhibition of platelet aggregation (Figure 4A). Compound 1.4,
showed significantly reduced antagonist activity towards both
P2Y1 and P2Y12, and had the highest IC50 for inhibition of platelet
aggregation.
Taken together, these results suggest that for optimal platelet
aggregation and platelet P2Y1 and P2Y12 receptor inhibition at
Figure 5. Stability and metabolism of the four diastereomers of compound 1 in human plasma at 37 6C. t1/2, half-life of first order
elimination. For other abbreviations, see Figure 1.
doi:10.1371/journal.pone.0094780.g005
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least one of the P1 and P4 phosphorothioates needs to be in the SP
configuration. Structurally, 1.2 and 1.3 differ only in the
configuration of the carbon atom of the chloromethylene group,
but differ significantly in their ability to antagonize P2Y12. Because
the absolute configuration of this carbon atom is assigned
arbitrarily to r or s, we cannot presently ascertain the absolute
configuration of the chloromethylene group that favors P2Y12
antagonism.
In the case of P2Y1, 1.4 (RPRP configuration) is the least active,
yet the difference between all diastereomers, and especially
between 1.2 and 1.3, is less pronounced if compared with the
differences in their activity observed for P2Y12 receptors.
Even though chiral phosphorothioate nucleotides have been
extensively used as probes for structural and mechanistic studies of
enzymes and receptors [15–17], and the question of molecular
recognition of P2Y12 receptors has been addressed in numerous
works (e.g., see [25,26] and references cited therein), to the best of
our knowledge the question of P2Y12 stereoselectivity has not been
addressed. Major et al. [27] studied P2Y1 receptors stereoselec-
tivity using the diastereomers of a-thioATP, a-thio-2-thiomethy-
lATP, and a-thio-2-chloroATPs as agonists of human P2Y1
receptors in HEK cells. The diastereomers with SP configuration
displayed 8–20 fold higher agonist activity than the RP diastereo-
mers. Assuming a similar mode of binding and identical binding
sites for ATP and Ap4A analogs, those results would corroborate
our conclusions for the preference of P2Y1 receptors for the SP
configuration at P1.
In the present study we observed better correlation between
P2Y12 inhibition and platelet aggregation inhibition than between
P2Y1 inhibition and platelet aggregation inhibition for the four
diastereomers of compound 1. Yet, in our opinion, this
observation cannot be used to discount a possible contribution
of P2Y1 inhibition to the overall platelet aggregation inhibition by
these compounds, especially taking into account the relatively
small number of binding sites of the P2Y1 receptors on the platelet
surface [28], and further studies will be necessary to shed light on
the relative contribution of the inhibition of each of the receptors.
Stereoselectivity in the plasma metabolism of the
diastereomers of compound 1
Because of the important physiological functions of dinucleoside
polyphosphates their intra- and extracellular levels are tightly
regulated [29]. Extracellular dinucleoside polyphosphates are
hydrolyzed by ecto-nucleotide pyrophosphatase/phosphodiester-
ases 1–3 (NPP1, PC-1; NPP2, autotoxin; NPP3, Gp130) [30].
Despite the important physiological role of NPP1-3, little is known
about their stereospecificity. Koziolkiewicz et al. [31] determined
that 39-exonuclease present in human plasma degrades phosphor-
othioate oligonucleotides with the RP configuration, whereas the
SP configuration is resistant to hydrolysis. More recently, Wojcik et
al. [32] showed that the enzyme responsible for this action is NPP1
(PC-1). The present results show that the degree of the stabilization
due to the thio modification depends significantly on its stereo
configuration, and that the phosphorothioate group in the SP
configuration is resistant to the hydrolytic action of those enzymes.
Thus compound 1.4, having both P1 and P4 in the RP
configuration was the least stable diastereomer, presumably being
degraded first to one mole of thioAMP and one mole of compound
2 in the RP configuration (actually, equal amount of diastereomers
2.3 and 2.4, see Figure 1). Both 2.3 and 2.4 have a
phosphorothioate group in the Rp configuration, and are further
quickly degraded to thioAMP and chloromethylene-bis-phospho-
nate. Diastereomers 1.2 and 1.3, which both have one
phosphorothioate group in the RP, and one in the SP configura-
tion, were hydrolyzed about 2 times slower than 1.4 to equimolar
amount of thioAMP and two stereo isomers of compound 2, which
were stable to further hydrolysis. This suggests that both 1.2 and
1.3 are hydrolyzed at the thiophosphate group in the RP
configuration, giving the SPS and SPR isomers of 2 (2.1 and
2.2, Figure 1), which both have their phosphorothioate group in
the Sp configuration, and resist further hydrolysis. Finally, 1.1,
having both P1 and P4 phosphorothioate groups in the SP
configuration did not show signs of hydrolysis even after very long
(up to 6 days) incubations in human plasma.
The physiologically important function of the ecto-nucleotide
pyrophosphatase/phosphodiesterase enzymes in regulating and
spatially modulating various purinergic signaling pathways, and
their value as therapeutic targets have been increasingly realized
[33,34], which makes the development of inhibitors or high
affinity probes of the NPP class an important research direction.
Compound 1.1 could be utilized as a convenient starting point for
that purpose. Our observation that 1.1 was completely resistant to
plasma degradation even after very long incubations opens the
possibility of crystallizing its complex with NPPs, thus providing
additional information for this important class of enzymes.
P2Y12 is among the most important targets of antiplatelet drugs
in current use and under development [35]. The potential of P2Y1
as a target for new antiplatelet drugs, or agents regulating the
vascular inflammation process has been recognized [36]. The
information in this study can be used to aid in elucidating the
structure and the mode of action of these targets, and in the design
of new inhibitors of scientific and/or therapeutic interest –
specifically inhibitors of both P2Y1 and P2Y12.
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